{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36816652", "DateRevised": {"Year": "2023", "Month": "02", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "29"}], "Language": ["eng"], "ELocationID": ["10.1021/acsomega.2c07885"], "Journal": {"ISSN": "2470-1343", "JournalIssue": {"Volume": "8", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Feb", "Day": "14"}}, "Title": "ACS omega", "ISOAbbreviation": "ACS Omega"}, "ArticleTitle": "Comparative Expression Analysis of Breakpoint Cluster Region-Abelson Oncogene in Leukemia Patients.", "Pagination": {"StartPage": "5975", "EndPage": "5982", "MedlinePgn": "5975-5982"}, "Abstract": {"AbstractText": ["Leukemia is a proliferative disorder of myeloid and lymphoid cells that may lead to death. Different types of leukemia have been reported, and several genetic and environmental factors are involved in their development. The Philadelphia chromosome causes the most common mutation known as breakpoint cluster region-Abelson oncogene (BCR-ABL1), which shows abnormal protein tyrosine kinase (PTK) activity. Basically, this activity is accountable for activating multiple pathways, including the inhibition of cell differentiation, controlled proliferation, and cell death. As a result of the absence of kinase activity, this mutation leads to the uncontrolled proliferation of leukocytes, causing chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and chronic lymphocytic leukemia (CLL). This study aimed to evaluate the level of BCR-ABL1 expression in patients with these types of leukemias through qPCR. In brief, PBMCs were isolated from blood samples of patients, RNA was extracted from PBMCs, cDNA was synthesized, and the transcript levels of BCR-ABL1 in patients with each type of leukemia were determined by qPCR. The clinical, demographical, and experimental data were analyzed among CML, AML, and ALL patients. Results: The BCR-ABL1 expression levels are variable in all studied groups and are 90, 30-35, and 1-2.5% in CML, ALL, and AML, respectively. Demographic characteristics such as gender, BMI, age, family history, and clinical parameters along with CBC are also associated with the prevalence and diagnosis of leukemia. In a comparative expression analysis, the expression of BCR-ABL1 is onefold high in AML, but four- and sevenfold high in ALL and CML, respectively, as compared with normal levels. Conclusions: In this study, a significant difference was observed in the expression levels of BCR-ABL1 between CML (<i>p</i> = 0.0043) and ALL (<i>p</i> = 0.0006) and between CML and AML groups, and a high expression of BCR-ABL1 was noted in CML as compared with ALL and AML."], "CopyrightInformation": "\u00a9 2023 The Authors. Published by American Chemical Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Molecular Virology Laboratory Centre for Applied Molecular Biology (CAMB), University of the Punjab, 87-West Canal Bank Road Thokar Niaz Baig, Lahore54590, Pakistan."}], "LastName": "Arshad", "ForeName": "Farah", "Initials": "F"}, {"Identifier": ["0000-0001-5857-0653"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology and Genetic Engineering, Hazara University, Mansehra21120, Khyber Pakhtunkhwa, Pakistan."}, {"Identifier": [], "Affiliation": "Molecular Virology Laboratory Centre for Applied Molecular Biology (CAMB), University of the Punjab, 87-West Canal Bank Road Thokar Niaz Baig, Lahore54590, Pakistan."}], "LastName": "Ali", "ForeName": "Amjad", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "District Medical Specialist Category-D Hospital Talash Dir Lower, Lower Dir23120, Khyber Pakhtunkhwa, Pakistan."}], "LastName": "Rehman", "ForeName": "Gauhar", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Center, University of Nizwa, Birkat-Al-Mouz, 616, P.O. Box 33, Nizwa616, Sultanate of Oman."}], "LastName": "Halim", "ForeName": "Sobia Ahsan", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology and Genetic Engineering, Hazara University, Mansehra21120, Khyber Pakhtunkhwa, Pakistan."}, {"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Center, University of Nizwa, Birkat-Al-Mouz, 616, P.O. Box 33, Nizwa616, Sultanate of Oman."}], "LastName": "Waqas", "ForeName": "Muhammad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Jazan45142, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants and Traditional Medicine Research Institute, National Center for Research, P.O. Box 2404, Khartoum11111, Sudan."}], "LastName": "Khalid", "ForeName": "Asaad", "Initials": "A"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah21955, Saudi Arabia."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": ["0000-0001-7851-6080"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Center, University of Nizwa, Birkat-Al-Mouz, 616, P.O. Box 33, Nizwa616, Sultanate of Oman."}], "LastName": "Khan", "ForeName": "Ajmal", "Initials": "A"}, {"Identifier": ["0000-0002-0815-5942"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Center, University of Nizwa, Birkat-Al-Mouz, 616, P.O. Box 33, Nizwa616, Sultanate of Oman."}], "LastName": "Al-Harrasi", "ForeName": "Ahmed", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "ACS Omega", "NlmUniqueID": "101691658", "ISSNLinking": "2470-1343"}, "CoiStatement": "The authors declare no competing financial interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Papaemmanuil E.; Gerstung M.; Bullinger L.; Gaidzik V. I.; Paschka P.; Roberts N. D.; Potter N. E.; Heuser M.; Thol F.; Bolli N.; et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 2016, 374, 2209\u20132221. 10.1056/NEJMoa1516192.", "ArticleIdList": ["10.1056/NEJMoa1516192", "PMC4979995", "27276561"]}, {"Citation": "R\u00fcegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J. Leukocyte Biol. 2006, 80, 682\u2013684. 10.1189/jlb.0606394.", "ArticleIdList": ["10.1189/jlb.0606394", "16849612"]}, {"Citation": "Collins S. J. Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr. Opin. Hematol. 2008, 15, 346\u2013351. 10.1097/MOH.0b013e3283007edf.", "ArticleIdList": ["10.1097/MOH.0b013e3283007edf", "18536573"]}, {"Citation": "Mitelman F.; Johansson B.; Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007, 7, 233\u2013245. 10.1038/nrc2091.", "ArticleIdList": ["10.1038/nrc2091", "17361217"]}, {"Citation": "Nacheva E. P.; Grace C. D.; Brazma D.; Gancheva K.; Howard-Reeves J.; Rai L.; Gale R. E.; Linch D. C.; Hills R. K.; Russell N.; et al. Does BCR/ABL 1 positive Acute Myeloid Leukaemia Exist?. Br. J. Haematol. 2013, 161, 541\u2013550. 10.1111/bjh.12301.", "ArticleIdList": ["10.1111/bjh.12301", "23521501"]}, {"Citation": "Verma D.; Kantarjian H. M.; Jones D.; Luthra R.; Borthakur G.; Verstovsek S.; Rios M. B.; Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009, 114, 2232\u20132235. 10.1182/blood-2009-02-204693.", "ArticleIdList": ["10.1182/blood-2009-02-204693", "PMC4828071", "19531657"]}, {"Citation": "Druker B. J.; Sawyers C. L.; Kantarjian H.; Resta D. J.; Reese S. F.; Ford J. M.; Capdeville R.; Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001, 344, 1038\u20131042. 10.1056/NEJM200104053441402.", "ArticleIdList": ["10.1056/NEJM200104053441402", "11287973"]}, {"Citation": "Hofmann W.-K.; Jones L. C.; Lemp N. A.; de Vos S.; Gschaidmeier H.; Hoelzer D.; Ottmann O. G.; Koeffler H. P. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99, 1860\u20131862. 10.1182/blood.V99.5.1860.", "ArticleIdList": ["10.1182/blood.V99.5.1860", "11861307"]}, {"Citation": "Mullighan C. G.; Goorha S.; Radtke I.; Miller C. B.; Coustan-Smith E.; Dalton J. D.; Girtman K.; Mathew S.; Ma J.; Pounds S. B.; et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446, 758\u2013764. 10.1038/nature05690.", "ArticleIdList": ["10.1038/nature05690", "17344859"]}, {"Citation": "Livak K. J.; Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2013 \u0394\u0394CT method. Methods 2001, 25, 402\u2013408. 10.1006/meth.2001.1262.", "ArticleIdList": ["10.1006/meth.2001.1262", "11846609"]}, {"Citation": "Urruticoechea A.; Alemany R.; Balart J.; Villanueva A.; Vi\u00f1als F.; Capella G. Recent advances in cancer therapy: an overview. Curr. Pharm. Des. 2010, 16, 3\u201310. 10.2174/138161210789941847.", "ArticleIdList": ["10.2174/138161210789941847", "20214614"]}, {"Citation": "Copland M.; J\u00f8rgensen H. G.; Holyoake T. L. Evolving molecular therapy for chronic myeloid leukaemia\u2014are we on target?. Hematology 2005, 10, 349\u2013359. 10.1080/10245330500234195.", "ArticleIdList": ["10.1080/10245330500234195", "16203604"]}, {"Citation": "Nowak D.; Stewart D.; Koeffler H. P. Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113, 3655\u20133665. 10.1182/blood-2009-01-198911.", "ArticleIdList": ["10.1182/blood-2009-01-198911", "PMC2943835", "19221035"]}, {"Citation": "Huang J.; Chan S. C.; Ngai C. H.; Lok V.; Zhang L.; Lucero-Prisno D. E. III; Xu W.; Zheng Z.-J.; Elcarte E.; Withers M.; Wong M. C. S. Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis. Front. Oncol. 2022, 12, 90429210.3389/fonc.2022.904292.", "ArticleIdList": ["10.3389/fonc.2022.904292", "PMC9355717", "35936709"]}, {"Citation": "Aziz Z.; Iqbal J.; Akram M.; Saeed S. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. Cancer 2007, 109, 1138\u20131145. 10.1002/cncr.22498.", "ArticleIdList": ["10.1002/cncr.22498", "17315159"]}, {"Citation": "Vos T.; Abajobir A. A.; Abate K. H.; Abbafati C.; Abbas K. M.; Abd-Allah F.; Abdulkader R. S.; Abdulle A. M.; Abebo T. A.; Abera S. F. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211\u20131259. 10.1016/S0140-6736(17)32154-2.", "ArticleIdList": ["10.1016/S0140-6736(17)32154-2", "PMC5605509", "28919117"]}, {"Citation": "Usmani S. Z.; Yunus S. A.; Jamal Y. Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. Asian Pac. J. Cancer Prev. 2009, 10, 1039\u20131040.", "ArticleIdList": ["20192579"]}, {"Citation": "Panda S. K.; Ravindran B. Isolation of human PBMCs. Bio-Protoc. 2013, 3, e323.10.21769/BioProtoc.323.", "ArticleIdList": ["10.21769/BioProtoc.323"]}, {"Citation": "Ye J.; Coulouris G.; Zaretskaya I.; Cutcutache I.; Rozen S.; Madden T. L. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinf. 2012, 13, 1\u201311. 10.1186/1471-2105-13-S6-S1.", "ArticleIdList": ["10.1186/1471-2105-13-S6-S1", "PMC3412702", "22708584"]}, {"Citation": "Prism G.6 GraphPad Software\nRRID: SCR_002798. 2019. https://www.graphpad.com/scientificsoftware/prism."}, {"Citation": "Arico M.; Schrappe M.; Hunger S. P.; Carroll W. L.; Conter V.; Galimberti S.; Manabe A.; Saha V.; Baruchel A.; Vettenranta K. Clinical outcome of children with newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia treated between 1995 and 2005. J. Clin. Oncol. 2010, 28, 4755\u20134761. 10.1200/JCO.2010.30.1325.", "ArticleIdList": ["10.1200/JCO.2010.30.1325", "PMC3020705", "20876426"]}, {"Citation": "Klonoff-Cohen H.; Navarro A.; Klonoff E. A. Late effects awareness website for pediatric survivors of acute lymphocytic leukemia. PLoS One 2018, 13, e019314110.1371/journal.pone.0193141.", "ArticleIdList": ["10.1371/journal.pone.0193141", "PMC5815604", "29451924"]}, {"Citation": "Corbin A. S.; Buchdunger E.; Pascal F.; Druker B. J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 2002, 277, 32214\u201332219. 10.1074/jbc.M111525200.", "ArticleIdList": ["10.1074/jbc.M111525200", "12077114"]}, {"Citation": "Haznedaro\u011flu \u0130. C. Current management of chronic myeloid leukemia with tyrosine kinase inhibitors. Turk. J. Hematol. 2013, 30, 247\u2013255. 10.4274/Tjh.2013.0108.", "ArticleIdList": ["10.4274/Tjh.2013.0108", "PMC3878539", "24385803"]}, {"Citation": "Larfors G.; Hallb\u00f6\u00f6k H.; Simonsson B. Parental age, family size, and offspring\u2019s risk of childhood and adult acute leukemia. Cancer Epidemiol., Biomarkers Prev. 2012, 21, 1185\u20131190. 10.1158/1055-9965.EPI-12-0178.", "ArticleIdList": ["10.1158/1055-9965.EPI-12-0178", "22539609"]}, {"Citation": "Eghtedar A.; Verstovsek S.; Estrov Z.; Burger J.; Cortes J.; Bivins C.; Faderl S.; Ferrajoli A.; Borthakur G.; George S.; et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012, 119, 4614\u20134618. 10.1182/blood-2011-12-400051.", "ArticleIdList": ["10.1182/blood-2011-12-400051", "PMC4081383", "22422826"]}, {"Citation": "White H. E.; Matejtschuk P.; Rigsby P.; Gabert J.; Lin F.; Wang Y. L.; Branford S.; M\u00fcller M. C.; Beaufils N.; Beillard E.; et al. Establishment of the first World Health Organization international genetic reference panel for quantitation of BCR-ABL mRNA. Blood 2010, 116, e111\u2013e117. 10.1182/blood-2010-06-291641.", "ArticleIdList": ["10.1182/blood-2010-06-291641", "20720184"]}, {"Citation": "Konoplev S.; Yin C. C.; Kornblau S. M.; Kantarjian H. M.; Konopleva M.; Andreeff M.; Lu G.; Zuo Z.; Luthra R.; Medeiros L. J. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk. Lymphoma 2013, 54, 138\u2013144. 10.3109/10428194.2012.701739.", "ArticleIdList": ["10.3109/10428194.2012.701739", "PMC3925981", "22691121"]}, {"Citation": "Network C. G. A. R. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368, 2059\u20132074. 10.1056/NEJMoa1301689.", "ArticleIdList": ["10.1056/NEJMoa1301689", "PMC3767041", "23634996"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "10"}, {"Year": "2023", "Month": "1", "Day": "6"}, {"Year": "2023", "Month": "2", "Day": "23", "Hour": "9", "Minute": "24"}, {"Year": "2023", "Month": "2", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "24", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "1", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["36816652", "PMC9933183", "10.1021/acsomega.2c07885"]}}], "PubmedBookArticle": []}